MAGEA3 and non-small cell lung carcinoma: Further evaluation of this vaccine in a phase II NSCLC study (NCT01853878) was terminated prematurely, as the benefit of CTA cancer vaccines in NSCLC was questioned given the strong immunosuppressive environment of NSCLC tumors and the lack of improvement in clinical outcomes of a phase III randomized MAGE-A3 vaccination study [67].